Gilead (GILD) CFO awarded RSUs, stock options and increases share holdings

Rhea-AI Filing Summary

Gilead Sciences Chief Financial Officer Andrew Dickinson reported routine equity compensation activity. On March 10, 2026, he exercised restricted stock units into 6,469 shares of common stock and received a new grant of 9,590 restricted stock units, each representing one future share.

He was also granted 35,880 non-qualified stock options with an exercise price of $148.56 per share, expiring on March 10, 2036. Following the RSU exercise, 3,147 shares of common stock were withheld to cover tax obligations, leaving him with 182,191 common shares and 30,647 restricted stock units directly owned.

The RSU and option grants vest over four years, with 25% vesting on the first anniversary of the grant and the remaining 75% vesting in 6.25% quarterly installments, aligning his compensation with long-term shareholder value.

Insider Trade Summary

6,469 shares exercised/converted

Mixed 5 txns

Insider Dickinson Andrew D

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	6,469	$0.00	--
Grant/Award	Restricted Stock Unit	9,590	$0.00	--
Grant/Award	Non-qualified Stock Option (Right to Buy)	35,880	$0.00	--
Exercise	Common Stock	6,469	$0.00	--
Tax Withholding	Common Stock	3,147	$148.56	$468K

Holdings After Transaction: Restricted Stock Unit — 21,057 shares (Direct); Non-qualified Stock Option (Right to Buy) — 35,880 shares (Direct); Common Stock — 185,338 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. The stock options have a four-year vesting schedule. 25% vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dickinson Andrew D

(Last) (First) (Middle)

GILEAD SCIENCES, INC.

333 LAKESIDE DRIVE

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		M		6,469	A	(1)	185,338	D
Common Stock	03/10/2026		F		3,147	D	$148.56	182,191	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	03/10/2026		M			6,469	(2)	(2)	Common Stock	6,469	(1)	21,057	D
Restricted Stock Unit	(1)	03/10/2026		A		9,590		(2)	(2)	Common Stock	9,590	(1)	30,647	D
Non-qualified Stock Option (Right to Buy)	$148.56	03/10/2026		A		35,880		(3)	03/10/2036	Common Stock	35,880	$0	35,880	D

Explanation of Responses:

1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

2. The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

3. The stock options have a four-year vesting schedule. 25% vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.

Remarks:

	/s/ Amy Kim by Power of Attorney for Andrew D. Dickinson	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Gilead Sciences (GILD) report for CFO Andrew Dickinson?

Gilead’s CFO Andrew Dickinson exercised 6,469 restricted stock units into common shares and received new grants of 9,590 restricted stock units plus 35,880 non-qualified stock options. These transactions are part of his equity compensation, not open-market buying or selling.

How many Gilead (GILD) shares does the CFO hold after these Form 4 transactions?

After the reported transactions, CFO Andrew Dickinson directly holds 182,191 shares of Gilead common stock and 30,647 restricted stock units. These holdings reflect equity already owned plus new grants, less shares withheld to cover tax obligations on the RSU vesting.

What equity awards did Gilead (GILD) grant its CFO on March 10, 2026?

On March 10, 2026, Gilead granted its CFO 9,590 restricted stock units and 35,880 non-qualified stock options with a $148.56 exercise price. These awards form part of his long-term incentive compensation linked to Gilead’s share performance over time.

How do the new Gilead (GILD) restricted stock units for the CFO vest?

The CFO’s restricted stock units follow a four-year vesting schedule: 25% vest on the first anniversary of the grant, with the remaining 75% vesting in 6.25% quarterly installments. Each vested unit converts into one share of Gilead common stock.

What are the terms of the new Gilead (GILD) stock options granted to the CFO?

The CFO received 35,880 non-qualified stock options with a $148.56 exercise price, expiring March 10, 2036. They vest over four years, with 25% vesting after one year and the remaining 75% vesting 6.25% quarterly, aligning rewards with long-term performance.

Were any Gilead (GILD) shares sold by the CFO in this Form 4 filing?

No open-market sales were reported. The only disposition was 3,147 shares withheld at $148.56 per share to satisfy tax obligations related to the restricted stock unit vesting, a standard non-market mechanism rather than a discretionary sale into the market.